Es ist ein Fehler aufgetreten!
Novartis Aktie
| 90.90 CHF | 0.68CHF | 0.75% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 84.31 |
| Novartis AG | 9.39 |
| Sandoz Family Foundation | 3.49 |
| Novartis Foundation For Employee Participation | 2.57 |
| The Vanguard Group, Inc. | 2.48 |
| Norges Bank Investment Management | 2.14 |
| Capital Research & Management Co. (Global Investors) | 1.93 |
| Wellington Management Co. LLP | 1.64 |
| UBS AG (Investment Management) | 1.61 |
| Capital Research & Management Co. (World Investors) | 1.50 |
| BlackRock Fund Advisors | 1.22 |
| Zürcher Kantonalbank (Investment Management) | 0.99 |
| Credit Suisse Asset Management (Schweiz) AG | 0.83 |
| Dodge & Cox | 0.63 |
| JPMorgan Asset Management (UK) Ltd. | 0.47 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 133'413 | 118'700 | 118'393 | 121'597 | 125'161 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.36 | 0.40 | 0.40 | 0.40 | 0.41 |
Bilanz (in Mio. EUR) - Aktiva
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 37'322 | 22'867 | 25'338 | 27'488 | 35'058 |
| Summe Anlagevermögen | 90'546 | 99'076 | 100'247 | 99'977 | 109'132 |
| Summe Aktiva | 124'967 | 132'037 | 132'519 | 129'833 | 143'578 |
Bilanz (in Mio. EUR) - Passiva
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 20'229 | 21'952 | 24'191 | 27'700 | 31'634 |
| Summe Fremdkapital | 54'573 | 54'838 | 56'403 | 57'498 | 66'003 |
| Summe Eigenkapital | 70'394 | 77'199 | 76'115 | 72'334 | 77'575 |
| Summe Passiva | 124'967 | 132'037 | 132'519 | 129'833 | 143'578 |
Adresse
| Lichtstrasse 35, 4056 Basel | |
| Telefon | 41613241111 |
| Fax | 41613248001 |
| Internet | http://www.novartis.com |
Management
|
Ameet Mallik
Head-Global Marketing, Value & Access |
|
Andreas von Planta, PhD
Independent Non-Executive Director |
|
Ann Marie Fudge, MBA
Independent Non-Executive Director |
|
Antonio Ligi
Head-Global Media Relations |
|
Bertrand Bodson PhD, MBA
Chief Digital Officer |
|
Charles L. Sawyers, MD
Independent Non-Executive Director |
|
Charlie Hough
VP & Global Head-Strategy |
|
Charlotte Pamer-Wieser, PhD
Secretary |
|
Dan Bar-Zohar, MD
Global Head-Neuroscience Development |
|
David Lebwohl
SVP & Franchise Global Program Head |
|
Elizabeth Theophille
Chief Technology & Digital Officer |
|
Enrico Cipro Vanni PhD, MBA
Vice Chairman |
|
Frans van Houten
Independent Non-Executive Director |
|
Hans Jörg Reinhardt, PhD
Independent Non-Executive Chairman |
|
Harry Werner Kirsch
Chief Financial Officer |
|
Isabella Zinck
Investor Relations Contact |
|
James E. Bradner, MD
Member-Executive Committee |
|
Janneke van der Kamp
Member Executive Committee |
|
Jeffrey Engelman, PhD
Vice President & Global Head-Oncology NIBR |
|
John Tsai, MD
Chief Medical Officer |
|
Klaus Moosmayer, PhD
Chief Ethics Risk & Compliance Officer |
|
Lilli Petruzzelli
Global Head-Immuno-Oncology |
|
Mark Levick
Global Head |
|
Mary Elizabeth Doherty
Independent Non-Executive Director |
|
Michael Willi
Group Head-Communications |
|
Mimi Huizinga, MD
VP & Head-Strategic Data |
|
Nancy C. Andrews MD, PhD
Independent Non-Executive Director |
|
Natacha Theytaz
Head-Internal Audit |
|
Patrice Bula
Director |
|
Paul Barrett
Global Head-External Communications |
|
Paul Hudson
Member-Executive Committee |
|
Pierre-Michel Bringer
Investor Relations Contact |
|
Samir Shah, MD
Global Head-Investor Relations |
|
Samit Hirawat
Head- Global Oncology Development |
|
Shannon Thyme Klinger, PhD
Group General Counsel |
|
Srikant T. Madhav Datar, PhD
Independent Non-Executive Director |
|
Steffen Lang, PhD
Global Head-Technical Operations |
|
Stephen Moran, PhD
Global Head-Strategy |
|
Steven Baert, MBA
Head-Human Resources |
|
Thomas Hungerbühler
Investor Relations Contact |
|
Ton Büchner, MBA
Independent Non-Executive Director |
|
Vasant Narasimhan, MD
Chief Executive Officer |
|
William Thomas Winters, MBA
Independent Non-Executive Director |